NMRA Quote, Financials, Valuation and Earnings

Coherus Oncology, Inc. has a net margin of -- compared to Neumora Therapeutics, Inc.'s net margin of -384.73%. Neumora Therapeutics, Inc.'s return on equity of -102.63% beat Coherus Oncology, Inc.'s return on equity of --.

Neumora Therapeutics, Inc. has a consensus price target of $9.17, signalling upside risk potential of 338.6%. On the other hand Coherus Oncology, Inc. has an analysts' consensus of $5.67 which suggests that it could grow by 319.75%. Given that Neumora Therapeutics, Inc. has higher upside potential than Coherus Oncology, Inc., analysts believe Neumora Therapeutics, Inc. is more attractive than Coherus Oncology, Inc..

Neumora Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Coherus Oncology, Inc. has a beta of 0.951, suggesting its less volatile than the S&P 500 by 4.926%.

Neumora Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Coherus Oncology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neumora Therapeutics, Inc. pays -- of its earnings as a dividend. Coherus Oncology, Inc. pays out -- of its earnings as a dividend.

Neumora Therapeutics, Inc. quarterly revenues are --, which are smaller than Coherus Oncology, Inc. quarterly revenues of $11.6M. Neumora Therapeutics, Inc.'s net income of -$56.8M is lower than Coherus Oncology, Inc.'s net income of -$44.5M. Notably, Neumora Therapeutics, Inc.'s price-to-earnings ratio is -- while Coherus Oncology, Inc.'s PE ratio is 1.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neumora Therapeutics, Inc. is -- versus 1.87x for Coherus Oncology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Puma Biotechnology, Inc. has a net margin of -- compared to Neumora Therapeutics, Inc.'s net margin of 16.24%. Neumora Therapeutics, Inc.'s return on equity of -102.63% beat Puma Biotechnology, Inc.'s return on equity of 38.49%.

Neumora Therapeutics, Inc. has a consensus price target of $9.17, signalling upside risk potential of 338.6%. On the other hand Puma Biotechnology, Inc. has an analysts' consensus of $3.50 which suggests that it could fall by -40.27%. Given that Neumora Therapeutics, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe Neumora Therapeutics, Inc. is more attractive than Puma Biotechnology, Inc..

Neumora Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Puma Biotechnology, Inc. has a beta of 1.177, suggesting its more volatile than the S&P 500 by 17.656%.

Neumora Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Puma Biotechnology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neumora Therapeutics, Inc. pays -- of its earnings as a dividend. Puma Biotechnology, Inc. pays out -- of its earnings as a dividend.

Neumora Therapeutics, Inc. quarterly revenues are --, which are smaller than Puma Biotechnology, Inc. quarterly revenues of $54.5M. Neumora Therapeutics, Inc.'s net income of -$56.8M is lower than Puma Biotechnology, Inc.'s net income of $8.8M. Notably, Neumora Therapeutics, Inc.'s price-to-earnings ratio is -- while Puma Biotechnology, Inc.'s PE ratio is 7.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neumora Therapeutics, Inc. is -- versus 1.38x for Puma Biotechnology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

TransMedics Group, Inc. has a net margin of -- compared to Neumora Therapeutics, Inc.'s net margin of 16.91%. Neumora Therapeutics, Inc.'s return on equity of -102.63% beat TransMedics Group, Inc.'s return on equity of 33.29%.

Neumora Therapeutics, Inc. has a consensus price target of $9.17, signalling upside risk potential of 338.6%. On the other hand TransMedics Group, Inc. has an analysts' consensus of $144.64 which suggests that it could grow by 14.08%. Given that Neumora Therapeutics, Inc. has higher upside potential than TransMedics Group, Inc., analysts believe Neumora Therapeutics, Inc. is more attractive than TransMedics Group, Inc..

Neumora Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison TransMedics Group, Inc. has a beta of 2.061, suggesting its more volatile than the S&P 500 by 106.067%.

Neumora Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TransMedics Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neumora Therapeutics, Inc. pays -- of its earnings as a dividend. TransMedics Group, Inc. pays out -- of its earnings as a dividend.

Neumora Therapeutics, Inc. quarterly revenues are --, which are smaller than TransMedics Group, Inc. quarterly revenues of $143.8M. Neumora Therapeutics, Inc.'s net income of -$56.8M is lower than TransMedics Group, Inc.'s net income of $24.3M. Notably, Neumora Therapeutics, Inc.'s price-to-earnings ratio is -- while TransMedics Group, Inc.'s PE ratio is 51.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neumora Therapeutics, Inc. is -- versus 8.76x for TransMedics Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ventyx Biosciences, Inc. has a net margin of -- compared to Neumora Therapeutics, Inc.'s net margin of --. Neumora Therapeutics, Inc.'s return on equity of -102.63% beat Ventyx Biosciences, Inc.'s return on equity of -45.75%.

Neumora Therapeutics, Inc. has a consensus price target of $9.17, signalling upside risk potential of 338.6%. On the other hand Ventyx Biosciences, Inc. has an analysts' consensus of $15.14 which suggests that it could grow by 84.9%. Given that Neumora Therapeutics, Inc. has higher upside potential than Ventyx Biosciences, Inc., analysts believe Neumora Therapeutics, Inc. is more attractive than Ventyx Biosciences, Inc..

Neumora Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ventyx Biosciences, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Neumora Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ventyx Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Neumora Therapeutics, Inc. pays -- of its earnings as a dividend. Ventyx Biosciences, Inc. pays out -- of its earnings as a dividend.

Neumora Therapeutics, Inc. quarterly revenues are --, which are smaller than Ventyx Biosciences, Inc. quarterly revenues of --. Neumora Therapeutics, Inc.'s net income of -$56.8M is lower than Ventyx Biosciences, Inc.'s net income of -$22.8M. Notably, Neumora Therapeutics, Inc.'s price-to-earnings ratio is -- while Ventyx Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Neumora Therapeutics, Inc. is -- versus -- for Ventyx Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.